30 Participants NeededMy employer runs this trial

Exercise for Peripheral Neuropathy

(CYCLE-CIPN Trial)

TL
CS
Overseen ByChristopher Sellar, PhD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Margie McNeely
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

CYCLE-CIPN is a proof-of-concept study designed to evaluate whether a prescribed aerobic exercise intervention has the potential to reduce the symptoms and functional impact of CIPN. The small number of participants in the proposed study will allow us to make decisions on the feasibility ("go/no-go") of a future larger-scale trial.

The protocol will assess feasibility and acceptability through recruitment, completion, adherence, program satisfaction, and safety. The study will also evaluate CIPN symptoms using both patient-reported and objective outcome measures, as well as fitness and quality of life outcomes. We aim to recruit 30 participants.

The Health Research Board of Alberta Cancer Committee has approved this study. Participants will participate in a stationary cycling-based aerobic exercise program biweekly for 12 weeks. Exercise sessions will be supervised and progressive, between 30 and 60 minutes each.

Who Is on the Research Team?

ML

Margaret L McNeely, PhD

Principal Investigator

University of Alberta

Are You a Good Fit for This Trial?

Inclusion Criteria

I am 18 years old or older.
My cancer is diagnosed at stage I, II, or III.
I have mild nerve damage from chemotherapy.
See 2 more

What Are the Treatments Tested in This Trial?

Interventions

  • Cycling-Based Aerobic Exercise Intervention

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Aerobic exercise interventionExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Margie McNeely

Lead Sponsor

Trials
1
Recruited
30+

University of Alberta

Lead Sponsor

Trials
957
Recruited
437,000+

Cross Cancer Institute

Collaborator

Trials
62
Recruited
19,200+